Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CANF

Can-Fite Biopharma Ltd ADR

Dec 26 • 11:58AM ET

1.48

Dollar change +0.05
Percentage change 3.50	%

Healthcare • Biotechnology • Israel • AMEX

Peers: TGTX AGEN PDSB IMMP APLS ATNM CGEN CASI CLRB BIVI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.86	Insider Own	-	Shs Outstand	4.53M	Perf Week	11.28%
Market Cap	14.70M	Forward P/E	-	EPS next Y	-0.05	Insider Trans	-	Shs Float	4.08M	Perf Month	-29.86%
Income	-7.63M	PEG	-	EPS next Q	-0.24	Inst Own	7.60%	Short Float	8.85%	Perf Quarter	-27.80%
Sales	0.74M	P/S	19.86	EPS this Y	58.37%	Inst Trans	-	Short Ratio	0.84	Perf Half Y	-42.19%
Book/sh	1.38	P/B	1.07	EPS next Y	96.00%	ROA	-79.22%	Short Interest	0.36M	Perf Year	-30.84%
Cash/sh	0.90	P/C	1.65	EPS next 5Y	-	ROE	-142.49%	52W Range	1.29 - 4.69	Perf YTD	-32.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.75%	ROI	-122.03%	52W High	-68.44%	Beta	1.34
Dividend TTM	-	Quick Ratio	4.90	Sales past 5Y	-22.15%	Gross Margin	-	52W Low	14.73%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	4.90	EPS Y/Y TTM	50.36%	Oper. Margin	-1102.96%	RSI (14)	37.36	Volatility	6.59% 10.82%
Employees	5	Debt/Eq	0.01	Sales Y/Y TTM	-8.27%	Profit Margin	-1027.46%	Recom	1.00	Target Price	14.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	67.30%	Payout	-	Rel Volume	0.69	Prev Close	1.43
Sales Surprise	100.00%	EPS Surprise	0.00%	Sales Q/Q	-21.32%	Earnings	Nov 29	Avg Volume	431.13K	Price	1.48
SMA20	-9.62%	SMA50	-26.59%	SMA200	-37.25%	Trades		Volume	122,085	Change	3.50%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-17	Initiated	Maxim Group	Buy	$7
Oct-19-16	Resumed	ROTH Capital	Buy
Aug-29-16	Resumed	Rodman & Renshaw	Buy	$6
Nov-30-15	Reiterated	H.C. Wainwright	Buy	$4 → $6
Mar-31-15	Reiterated	H.C. Wainwright	Buy	$7 → $3
Mar-30-15	Downgrade	ROTH Capital	Buy → Neutral	$20 → $2.40
Dec-29-14	Reiterated	ROTH Capital	Buy	$28 → $20
Nov-18-14	Initiated	H.C. Wainwright	Buy	$7

Dec-09-24 09:55AM	Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now (Zacks)
Dec-04-24 07:00AM	8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug (GlobeNewswire) -20.10%
Nov-22-24 09:00AM	60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Nov-11-24 07:00AM	Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial (GlobeNewswire)
Nov-05-24 07:28AM	Can-Fite BioPharma Secures Australian Patent for Obesity Drug (TipRanks)
07:08AM	Loading…
Nov-04-24 07:08AM	Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia (GlobeNewswire)
Oct-18-24 09:06AM	Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson (GlobeNewswire) +6.30%
Oct-09-24 07:00AM	FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer (GlobeNewswire) +15.20%
Oct-07-24 07:00AM	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on October 29 (GlobeNewswire)
Sep-24-24 07:00AM	Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis (GlobeNewswire)
Sep-16-24 07:00AM	Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health (GlobeNewswire)
Aug-30-24 09:48AM	Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-29-24 08:15AM	Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (GlobeNewswire)
Aug-09-24 09:00AM	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Aug-08-24 07:01PM	Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds (GlobeNewswire) +12.50%
07:00AM	Loading…
Jul-29-24 07:00AM	Can-Fite Provides Namodenoson Patent Update (GlobeNewswire) -13.21%
Jul-17-24 07:00AM	Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8 (GlobeNewswire)
Jul-11-24 07:00AM	Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-01-24 07:00AM	Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson (GlobeNewswire)
Jun-28-24 07:00AM	Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fites Partner Vetbiolix (Business Wire)
Jun-24-24 07:00AM	Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver (Business Wire) +5.32%
Jun-10-24 07:00AM	Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study (Business Wire)
Jun-05-24 07:00AM	Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study (Business Wire)
May-29-24 07:00AM	Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases (Business Wire)
May-27-24 07:00AM	Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 (Business Wire)
May-23-24 07:00AM	Join Can-Fites Exclusive Live Investor Webinar and Q&A Session on June 6 (Business Wire)
May-13-24 07:00AM	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study (Business Wire)
May-10-24 09:00AM	Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
06:23AM	Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial (Clinical Trials Arena)
May-09-24 07:00AM	Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study (Business Wire) +6.03%
07:00AM	Loading…
May-06-24 07:00AM	Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 (Business Wire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 07:00AM	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal (Business Wire)
Apr-15-24 07:00AM	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH (Business Wire)
Apr-03-24 07:00AM	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients (Business Wire)
Apr-01-24 07:00AM	Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV (Newsfile)
Mar-28-24 07:00AM	Can-Fite Reports 2023 Financial Results and Clinical Update (Business Wire)
Mar-11-24 07:00AM	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference (Business Wire)
Feb-28-24 07:00AM	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada (Business Wire)
Jan-30-24 07:00AM	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication (Business Wire)
Jan-29-24 07:00AM	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study (Business Wire) +7.14%
Dec-20-23 07:00AM	The Anti-Obesity Effect of Can-Fites Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies (Business Wire)
Dec-18-23 07:00AM	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan (Business Wire)
Dec-04-23 07:00AM	Can-Fites Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development (Business Wire)
Nov-30-23 07:00AM	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update (Business Wire)
Nov-22-23 07:23AM	Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson (Zacks)
Nov-21-23 01:53PM	Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds (GlobeNewswire) +6.73%
07:00AM	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson (Business Wire)
Nov-01-23 07:00AM	Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track (Business Wire)
Oct-30-23 09:55AM	Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
07:00AM	Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action (Business Wire)
Oct-27-23 10:00AM	Best Momentum Stocks to Buy for October 27th (Zacks)
06:07AM	New Strong Buy Stocks for October 27th (Zacks)
Oct-26-23 07:00AM	Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs (Business Wire)
Oct-09-23 07:00AM	Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies (Business Wire) -11.47%
Sep-27-23 07:00AM	Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) (Business Wire)
Sep-07-23 07:00AM	Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference (Business Wire)
Aug-31-23 07:00AM	Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (Business Wire)
Aug-24-23 07:10AM	Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome (Business Wire)
Aug-18-23 07:00AM	Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis (Business Wire)
Aug-08-23 07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Jul-17-23 07:00AM	Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation (Business Wire)
Jul-11-23 07:00AM	Presenting on the Emerging Growth Conference on July 12 & 13 Register Now (GlobeNewswire)
Jul-07-23 07:00AM	Can-Fite to Present at the Emerging Growth Conference on July 13, 2023 (Business Wire)
Jun-29-23 07:00AM	Can-Fite Receives U.S. FDAs Go Ahead for Piclidenoson Psoriasis Registration Plan (Business Wire)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks) +6.46%
Jun-13-23 07:00AM	Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson (Business Wire) +11.36%
Jun-02-23 07:00AM	Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston (Business Wire)
Jun-01-23 07:00AM	Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update (Business Wire)
May-30-23 07:00AM	Can-Fite: Namodenosons Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) (Business Wire) +10.04%
May-15-23 07:00AM	Can-Fite: Presenting Namodenosons New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023 (Business Wire)
May-10-23 12:00PM	All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy (Zacks)
May-09-23 07:00AM	Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients (Business Wire)
May-02-23 07:00AM	Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists (Business Wire) +14.29%
Apr-24-23 07:00AM	Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization (Business Wire)
Apr-10-23 07:00AM	Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment (Business Wire)
Mar-30-23 07:15AM	Can-Fite Reports 2022 Financial Results & Provides Clinical Update (Business Wire) +5.65%
Mar-16-23 07:00AM	Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson (Business Wire)
Mar-13-23 07:00AM	Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting (Business Wire)
Feb-14-23 07:00AM	Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo (Business Wire) -6.36%
Jan-24-23 07:00AM	Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical StudiesA Patent Has Been Filed (Business Wire) -6.32%
Jan-11-23 09:04AM	Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement (Business Wire) -16.13%
Jan-10-23 07:00AM	Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow (Business Wire)
Dec-30-22 04:30PM	Can-Fite Announces ADS Ratio Change (Business Wire) -5.69%
Dec-29-22 10:18AM	Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA (Zacks)
Dec-28-22 10:21AM	Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer (Benzinga) +8.17%
07:00AM	Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer (Business Wire)
Dec-27-22 08:00AM	Multiple Shots On Goal: Can-Fites Late-Stage Clinical Pipeline Hits Positive Results (News Direct) -6.26%
Dec-08-22 07:00AM	Can-Fites Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets Osteoarthritis (Business Wire)
Nov-25-22 07:00AM	Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update (Business Wire)
Nov-10-22 02:13PM	Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates (Zacks)
Nov-04-22 10:54AM	Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat (Zacks)
10:40AM	Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss (Zacks)
Nov-02-22 07:15AM	Can-Fite: Positive New Data from its Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston (Business Wire)
Oct-31-22 09:15AM	This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers (News Direct)
Oct-25-22 07:00AM	Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting® (Business Wire) +10.02%
Oct-13-22 07:00AM	Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference (Business Wire)
Sep-23-22 08:00AM	Can-Fite BioPharma Ltd. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -7.79%
Sep-12-22 07:00AM	Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology (Business Wire)
Aug-25-22 07:00AM	Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update (Business Wire) +9.70%

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CANF

Can-Fite Biopharma Ltd ADR

Upgrade your FINVIZ experience